Please login to the form below

TNBC

This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.

Tecentriq combo fails in advanced triple negative breast cancer

Merck’s drug suffered a rare set back last year when it failed to show benefits compared to standard chemotherapy in advanced TNBC. ... Despite the fail in TNBC, Keytruda is far ahead of its rivals in terms of revenues, bringing in $11bn last year alone

Latest news

Merck chases Roche with triple-negative breast cancer data for Keytruda

TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide, approximately 300, 000 cases every year. ... Meanwhile, Merck is also carrying out two additional studies of Keytruda to try to
Roche posts minor sales miss in Q4 as biosimilar pressure grows

cancer (NSCLC) and triple-negative breast cancer (TNBC).
Merck CFO: we’re not only about Keytruda

Merck also pointed to the potential for Keytruda growth in new indications like renal cell carcinoma, adjuvant melanoma, small-cell lung cancer (SCLC) and triple-negative breast cancer (TNBC), as well
Roche eyes filings for Tecentriq/Avastin combo in liver cancer

Tecentriq is already carving out a niche in indications like triple-negative breast cancer (TNBC) and extensive-stage small cell lung cancer (ES-CLC) where it isn’t facing direct competition
NICE turns down Roche’s Tecentriq for triple-negative breast cancer

negative breast cancer (TNBC), an aggressive form of the disease with few treatment options. ... diagnosed with TNBC in England would be eligible for treatment with the regimen if an access deal can be agreed.

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

Trop2 is a transmembrane glycoprotein overexpressed in many epithelial cancer cells, including TNBC.
Deal Watch January 2018

The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward: ...
Can eLearning improve patient recruitment and retention?: Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?: Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...